NCT01630200View on ClinicalTrials.gov

Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Chronic Obstructive Pulmonary Disease and Allied Conditions
Interventions
DRUG

Roflumilast

Roflumilast coated tablet, 500µg oral application, once daily in the morning

DRUG

Placebo

Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning

Trial Locations (1)

1140

Deparment for Respiratory and Critical Care Medicine, Otto Wangner Hospital, Vienna

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

lead

LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology

NETWORK

NCT01630200 - Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter